Evidence map›Paper›PMID 39918315›Full record

ArticleAntimicrobial agents and chemotherapy2025

Xpert MTB/RIF Ultra-resistant and MTBDR

Yonas Ghebrekristos, Aysha Ahmed, Natalie Beylis, Sarishna Singh, Christoffel Opperman, Fahd Naufal, Megan Folkerts, David Engelthaler, Erick Auma, Rouxjeane Venter and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Heteroresistance inFrontiers in cellular and infection microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yonas GhebrekristosDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Aysha AhmedNational Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa.
Natalie BeylisDivision of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Sarishna SinghDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Christoffel OppermanDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-6676-5431
Fahd NaufalUniversity of California San Francisco, San Francisco, California, USA.
Megan FolkertsTranslational Genomics Research Institute, Phoenix, Arizona, USA.
David EngelthalerTranslational Genomics Research Institute, Phoenix, Arizona, USA.ORCID 0000-0001-5945-059X
Erick AumaDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Rouxjeane VenterDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Ghowa BooleyDivision of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
John MetcalfeUniversity of California San Francisco, San Francisco, California, USA.
Robin WarrenDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Grant TheronDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-9216-2415

Funding

The Center for Innovation in Point-of-Care Technologies for HIV/AIDS atNorthwestern University (C-THAN) Supplemental RequestU54EB027049 · NIBIB · NORTHWESTERN UNIVERSITY · PI Chad J Achenbach, SALLY Maureen MCFALL · 2018 to 2026
$24.0M
Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)U01AI152087 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CATTAMANCHI, ADITHYA, DENKINGER, CLAUDIA MARIA · 2020 to 2024
$19.3M
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infectionR01AI131939 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGELTHALER, DAVID M, METCALFE, JOHN ZAPATA · 2018 to 2023
$3.9M
HIV and Mycobacterial Disease in MaliD43TW010350 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI MAIGA, ALMOUSTAPHA ISSIAKA, MURPHY, ROBERT LEO · 2016 to 2025
$3.0M
Pre- and post-treatment lung microbiota, metabolome and immune signatures at the site of disease in patients with active pulmonary tuberculosisR01AI136894 · NIAID · STELLENBOSCH UNIVERSITY · PI THERON, GRANT DE VOS · 2019 to 2023
$678k
EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership (EDCTP) RIA2020I-3305 CAGE-TBFIC NIH HHS D43 TW010350HHS | National Institutes of Health (NIH) D43TW010350 U01AI152087 U54EB027049 R01AI136894NIAID NIH HHS R01 AI131939NIAID NIH HHS R01 AI136894NIAID NIH HHS U01 AI152087NIBIB NIH HHS U54 EB027049
6 · The paper itself

Abstract

Xpert MTB/RIF Ultra (Ultra)-detected rifampicin-resistant tuberculosis (TB) is often programmatically confirmed using MTBDR

Indexed as

Antitubercular AgentsMycobacterium tuberculosisRifampinTuberculosis, Multidrug-ResistantBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesDrug Resistance, BacterialHigh-Throughput Nucleotide SequencingHumansMicrobial Sensitivity TestsOxidoreductasesSouth AfricaSputumAntitubercular AgentsBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesInhA protein, MycobacteriumkatG protein, Mycobacterium tuberculosisOxidoreductasesRifampinrpoB protein, Mycobacterium tuberculosisdiagnosisheteroresistancerifampicin susceptibilitytuberculosis

Identifiers

PMID39918315
PMCPMC11881552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.